financetom financetom
Business
financetom
/
Business
/
What's Happening With PDD Holdings Stock?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Happening With PDD Holdings Stock?
Mar 25, 2024 8:51 AM

PDD Holdings Inc ( PDD ) – ADR shares are trading lower by 2.5% to $119.87 during Monday’s session. The stock is trading lower, possibly due to profit-taking, following its surge to a new 52-week high after reporting earnings last Wednesday.

PDD reported impressive fourth-quarter fiscal 2023 results, with revenue growing by 123% year-on-year to $12.52 billion (CNY88.88 billion), beating expectations. Adjusted earnings per ADS were $2.40 (CNY17.32), surpassing estimates.

Revenues from online marketing services and others increased by 57% year-on-year to $6.86 billion, and revenues from transaction services jumped by 357% year-on-year to $5.66 billion…

Is PDD A Good Stock To Buy?

An investor or trader’s decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision.

For example, for PDD Holdings ( PDD ), you’ll notice that earnings in its last quarter grew 50.0% source. As an investor, you’ll want to decide whether that’s better or worse than what you’d like to see among stocks in your portfolio.

On the valuation side, PDD Holdings’s price to earnings ratio – a measure of how much an investor pays for the company’s earnings – is compressed 25.56% in the current quarter when compared with last year. That places it below similar businesses like Amazon.comAlibaba Gr HoldingMercadoLibre in its sector. You’ll need to decide whether that makes it more or less attractive based on how you think the company will perform over time.

There are many different valuation metrics that may help you make a decision. Find more on PDD Holdings’s quote page, or if you’d like a deeper dive in an advanced program, try Benzinga PRO for free.

According to data from Benzinga Pro, PDD has a 52-week high of $152.99 and a 52-week low of $59.67.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2024 - www.financetom.com All Rights Reserved